Apellis Pharmaceuticals, Inc. clinical trials

Acquired by Biogen, May 14, 2026 · source ↗

The registry lists 28 studies whose lead sponsor is Apellis Pharmaceuticals, Inc.. 3 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 2, 2026.

Studies

Recruiting first, then most recently updated. Showing 28 of 28. All Biogen studies →

• A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental GlomerulosclerosisRecruitingNCT07213960Phase 2/3

  Sponsor listed in the registry: Apellis Pharmaceuticals, Inc. · First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen

• A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)RecruitingNCT04901936Phase 2

  Sponsor listed in the registry: Apellis Pharmaceuticals, Inc. · First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen

• A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular DegeneratioRecruitingNCT07215390Phase 2

  Sponsor listed in the registry: Apellis Pharmaceuticals, Inc. · First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen

• Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft TransplantationWithdrawnNCT07020832Phase 3

  Sponsor listed in the registry: Apellis Pharmaceuticals, Inc. · First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen

• An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMDCompletedNCT04770545Phase 3

  Sponsor listed in the registry: Apellis Pharmaceuticals, Inc. · First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen

• Pegcetacoplan Long Term Safety and Efficacy Extension StudyCompletedNCT03531255Phase 3

  Sponsor listed in the registry: Apellis Pharmaceuticals, Inc. · First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen

• A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular DegenerationActive, not recruitingNCT06161584

  Sponsor listed in the registry: Apellis Pharmaceuticals, Inc. · First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen

• Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGNCompletedNCT04572854Phase 2

  Sponsor listed in the registry: Apellis Pharmaceuticals, Inc. · First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen

• An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative GlomerulonephritisActive, not recruitingNCT05809531Phase 3

  Sponsor listed in the registry: Apellis Pharmaceuticals, Inc. · First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen

• Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative GlomerulonephritisCompletedNCT05067127Phase 3

  Sponsor listed in the registry: Apellis Pharmaceuticals, Inc. · First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen

• Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled SyringeCompletedNCT07214740Phase 3

  Sponsor listed in the registry: Apellis Pharmaceuticals, Inc. · First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen

• C3G/Primary IC-MPGN EAPApproved for marketingNCT04729062

  Sponsor listed in the registry: Apellis Pharmaceuticals, Inc. · First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen

• MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)TerminatedNCT04579666Phase 2

  Sponsor listed in the registry: Apellis Pharmaceuticals, Inc. · First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen

• Phase II Study Assessing Safety and Efficacy of APL-2 in GlomerulopathiesCompletedNCT03453619Phase 2

  Sponsor listed in the registry: Apellis Pharmaceuticals, Inc. · First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen

• Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)CompletedNCT03226678Phase 2

  Sponsor listed in the registry: Apellis Pharmaceuticals, Inc. · First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen

• Geographic Atrophy Long-Terms Outcomes StudyCompletedNCT06499571

  Sponsor listed in the registry: Apellis Pharmaceuticals, Inc. · First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen

• A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular DegenerationCompletedNCT03525613Phase 3

  Sponsor listed in the registry: Apellis Pharmaceuticals, Inc. · First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen

• Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular DegenerationCompletedNCT03525600Phase 3

  Sponsor listed in the registry: Apellis Pharmaceuticals, Inc. · First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen

• A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNHCompletedNCT04085601Phase 3

  Sponsor listed in the registry: Apellis Pharmaceuticals, Inc. · First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen

• Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)CompletedNCT03500549Phase 3

  Sponsor listed in the registry: Apellis Pharmaceuticals, Inc. · First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen

• A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19CompletedNCT04402060Phase 1/2

  Sponsor listed in the registry: Apellis Pharmaceuticals, Inc. · First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen

• Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic AtrophyCompletedNCT03777332Phase 1

  Sponsor listed in the registry: Apellis Pharmaceuticals, Inc. · First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen

• Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects.CompletedNCT02588833Phase 1

  Sponsor listed in the registry: Apellis Pharmaceuticals, Inc. · First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen

• A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNHCompletedNCT02264639Phase 1

  Sponsor listed in the registry: Apellis Pharmaceuticals, Inc. · First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen

• A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNHCompletedNCT03593200Phase 2

  Sponsor listed in the registry: Apellis Pharmaceuticals, Inc. · First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen

• Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic AtrophyCompletedNCT02503332Phase 2

  Sponsor listed in the registry: Apellis Pharmaceuticals, Inc. · First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen

• Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMDCompletedNCT02461771Phase 1

  Sponsor listed in the registry: Apellis Pharmaceuticals, Inc. · First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen

• Pegcetacoplan (APL-2) in Neovascular AMDTerminatedNCT03465709Phase 1/2

  Sponsor listed in the registry: Apellis Pharmaceuticals, Inc. · First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen